CAR-T Therapy Shows Increasing Remissions in Autoimmune Diseases with Rising Experimentation and Investment

CAR-T cell therapy, a treatment that engineers patients' immune cells to attack diseased cells, has produced remissions in autoimmune diseases. Originally approved for certain blood cancers, the approach is now being tested for conditions where the immune system attacks healthy tissues, such as systemic lupus erythematosus and rheumatoid arthritis.

STAT News reported on cases where patients achieved complete remission after receiving the therapy.

In one example, a patient with lupus entered remission following CAR-T treatment, with no signs of disease activity months later. Similar outcomes have been observed in trials for multiple sclerosis and other autoimmune disorders. These results build on earlier studies that first demonstrated the therapy's potential beyond oncology.

companies have launched multiple clinical trials to evaluate CAR-T for autoimmune applications.

Bristol Myers Squibb, for instance, is conducting studies on its CAR-T product, which received FDA approval for lymphoma in 2022. Other firms, including Novartis and Kyverna Therapeutics, are investing in similar programs targeting B cells, which play a key role in autoimmune responses.

The therapy works by extracting T cells from a patient, genetically modifying them to recognize and eliminate problematic immune cells, then reinfusing them.

This process can lead to sustained remissions, unlike traditional treatments that often require ongoing medication. However, challenges include high costs, manufacturing complexities, and potential side effects like cytokine release syndrome.

in CAR-T for autoimmune diseases has increased, with venture funding supporting startups like Cabaletta Bio and Equillium.

STAT News noted that the field is seeing a surge in experimentation, driven by early successes in small patient cohorts. Regulatory bodies, such as the FDA, have granted breakthrough therapy designations to some candidates, accelerating development.

Patients with severe, treatment-resistant autoimmune conditions stand to benefit most, as current therapies like immunosuppressants carry risks of infection and incomplete control.

Broader adoption could expand access to curative options, though long-term safety data remains limited. Ongoing trials aim to address these gaps and determine optimal patient selection. Next steps include larger phase 2 and 3 trials to confirm efficacy and safety across diverse populations.

Results from these studies, expected in the coming years, will influence regulatory approvals and insurance coverage. The evolution of CAR-T from cancer to autoimmune use highlights its versatility in immune modulation.